Macimorelin vs hGHRH(1-40)OH
Head-to-head comparison of Macimorelin (Macimorelin acetate (AEZS-130)) and hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Macimorelin | hGHRH(1-40)OH |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Macimorelin acetate (AEZS-130) | Human growth hormone-releasing factor (1-40) hydroxyl |
| Molecular Weight | N/A | N/A |
| Half-Life | about 4-6 hours | 5-20 minutes |
| Amino Acids | N/A | 40 |
| Typical Dose | 0.5 mg/kg single oral dose | 1-2 mcg/kg |
| Route | Oral | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 85 |
| Research Status | Clinical | Clinical Research |
Macimorelin Benefits
- ✓diagnostic GH stimulation
- ✓single oral dose
- ✓rapid measurable GH response
- ✓high clinical utility
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
Macimorelin Dosing
0.5 mg/kg orally as a single dose|fasted testing conditions|serial GH sampling after administration
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
Macimorelin Side Effects
- ⚠dysgeusia or taste disturbance
- ⚠nausea
- ⚠headache
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Research Overview
Macimorelin
Macimorelin has been validated in clinical testing as an oral alternative to injectable GH stimulation tests. Its short-term use makes it a useful translational tool for evaluating pituitary GH reserve.
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.